Catalog No.
PMK86001
Species reactivity
Mouse
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Mouse RNF43 (Gln44-Lys189).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
E3 ubiquitin-protein ligase RNF43, RING finger protein 43, RING-type E3 ubiquitin transferase RNF43, RNF43
Purification
Purified by antigen affinity column.
Accession
Q5NCP0
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Structure-Guided Development of Chemically Tailored Peptide Binders of RNF43/ZNRF3 to Enable Versatile Design of Membrane Protein-Targeting PROTACs., PMID:40000409
Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration., PMID:39235609
Targeted protein degradation systems to enhance Wnt signaling., PMID:38847394
DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations., PMID:37992266
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers., PMID:37482749
Issues with RNF43 antibodies to reliably detect intracellular location., PMID:37023034
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer., PMID:36811382
Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors., PMID:36358851
Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA., PMID:36202008
Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins., PMID:35481357
Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma., PMID:34973294
An Early-Onset Advanced Rectal Cancer Patient With Increased KRAS Gene Copy Number Showed A Primary Resistance to Cetuximab in Combination With Chemotherapy: A Case Report., PMID:34888240
Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1., PMID:33395526
Unlike LGR4, LGR5 potentiates Wnt-β-catenin signaling without sequestering E3 ligases., PMID:33262293
Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer., PMID:33202731
Loss of RNF43 Function Contributes to Gastric Carcinogenesis by Impairing DNA Damage Response., PMID:33188943
Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers., PMID:31949927
Surrogate R-spondins for tissue-specific potentiation of Wnt Signaling., PMID:31914456
RNF43 ubiquitinates and degrades phosphorylated E-cadherin by c-Src to facilitate epithelial-mesenchymal transition in lung adenocarcinoma., PMID:31286874
Anti-LRP5/6 VHHs promote differentiation of Wnt-hypersensitive intestinal stem cells., PMID:30664649
Acquired resistance to immunotherapy in MMR-D pancreatic cancer., PMID:30458888
A synthetic anti-Frizzled antibody engineered for broadened specificity exhibits enhanced anti-tumor properties., PMID:30183492
IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides., PMID:29498403
Molecular genetics and targeted therapy of WNT-related human diseases (Review)., PMID:28731148
Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer., PMID:28266765
Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors., PMID:27869803
Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment., PMID:27341591
For research use only. Not for human or drug use.
